Rebecca C. Arend

NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025

Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial

Genomic alterations, molecularly targeted therapy, and survival: a real-world Endometrial Cancer Molecularly Targeted Therapy Consortium cohort study

Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology

Age-specific incidence and five-year relative survival of endometrial cancer histotypes by race and ethnicity among US women, 2000 to 2019

HER2 alterations across solid tumors: implications for comprehensive testing

Evaluation of the combination lenvatinib and pembrolizumab in endometrial cancer; a real world multi-institutional review of practice patterns, efficacy and tolerability

Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?

Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors

A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator

Targeting Mediator Kinase Cyclin-Dependent Kinases 8/19 Potentiates Chemotherapeutic Responses, Reverses Tumor Growth, and Prolongs Survival from Ovarian Clear Cell Carcinoma

Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology

Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine

Targeted therapy in high grade serous ovarian Cancer: A literature review

Uterine cancer incidence trends and 5-year relative survival by race/ethnicity and histology among women under 50 years

A phase 1/2 study of ubamatamab (REGN4018), a MUC16×CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti–PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer.

Niraparib, Dostarlimab, and Bevacizumab as Combination Therapy in Pretreated, Advanced Platinum-Resistant Ovarian Cancer: Findings From Cohort A of the OPAL Phase II Trial

Bridging the Gap from Bench to Bedside: A Call for <i>In Vivo</i> Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-oncology Research

Analysis of 20 Independently Performed Assays to Measure Homologous Recombination Deficiency (HRD) in Ovarian Cancer: Findings From the Friends' HRD Harmonization Project

Activin levels correlate with lymphocytic infiltration in epithelial ovarian cancer

Glycosaminoglycan modifications of betaglycan regulate ectodomain shedding to fine-tune TGF-β signaling responses in ovarian cancer

A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment

Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods

Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024

Proteogenomic insights suggest druggable pathways in endometrial carcinoma

TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes

Ofranergene Obadenovec (Ofra-Vec, VB-111) With Weekly Paclitaxel for Platinum-Resistant Ovarian Cancer: Randomized Controlled Phase III Trial (OVAL Study/GOG 3018)

Differential outcomes and immune checkpoint inhibitor response among endometrial cancer patients with MLH1 hypermethylation versus MLH1 “Lynch-like” mismatch repair gene mutation